# Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

> **NCT01836653** · PHASE2 · COMPLETED · sponsor: **EPS Corporation** · enrollment: 122 (actual)

## Conditions studied

- Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab
- **DRUG:** L-OHP
- **DRUG:** l-LV
- **DRUG:** 5-FU
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT01836653
- **Lead sponsor:** EPS Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836653, "Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01836653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*